Managing Pregnancy-Induced Hypertension

1. Executive Summary

Hypertensive disorders of pregnancy (HDP) represent a significant and growing public health challenge, affecting 5% to 10% of all pregnancies globally and serving as a leading cause of maternal and perinatal morbidity and mortality.¹ This report provides a comprehensive, evidence-based framework for the management of HDP, moving beyond the historical view of a transient pregnancy complication to a contemporary understanding of a multi-systemic disorder with profound and lasting health implications for both the mother and child. The report synthesizes current knowledge on the pathophysiology, risk stratification, and a full spectrum of management strategies, from preconception prevention to acute care and critical long-term follow-up.

A central theme of this analysis is the imperative for a paradigm shift in clinical practice. The traditional approach of managing HDP as an acute, gestational-specific condition is no longer tenable. The pathogenesis, rooted in abnormal placentation and maternal endothelial dysfunction, requires a proactive, preventive approach for at-risk individuals, primarily through the use of low-dose aspirin and targeted lifestyle modifications. Furthermore, the acute management phase during pregnancy must integrate a blend of standard clinical surveillance with emerging diagnostic technologies and patient-empowered home monitoring to prevent rapid disease progression and catastrophic outcomes.

Perhaps the most critical conclusion drawn from contemporary research is that delivery of the placenta, while resolving the immediate threat, is not a “cure” for HDP. The condition leaves a lasting physiological memory, creating a foundation for a lifetime of increased risk for cardiovascular disease, stroke, and chronic hypertension in the mother. Concurrently, the intrauterine environment in HDP predisposes the offspring to lifelong health challenges, including elevated blood pressure and altered cardiac development. This intergenerational impact necessitates a fundamental change in care models, requiring a seamless transition from obstetric care to a collaborative, multidisciplinary approach involving primary care and cardiology for the mother, and dedicated surveillance for the child. This report concludes with a call for renewed focus on bridging the gap between scientific discovery and clinical implementation, emphasizing the urgent need for new diagnostic tools, therapies, and formalized long-term follow-up guidelines to improve outcomes for all affected individuals.

2. Introduction: The Evolving Landscape of Hypertensive Disorders of Pregnancy (HDP)

Hypertensive disorders of pregnancy encompass a spectrum of conditions that complicate a substantial proportion of pregnancies, posing significant risks to both the mother and the developing fetus. The traditional terminology and diagnostic criteria for these conditions have undergone considerable evolution, moving towards a more nuanced and clinically useful classification that emphasizes multi-systemic involvement and disease severity. The modern understanding of HDP necessitates a clear, precise definition of its constituent parts to guide appropriate management strategies.

2.1. Defining the Spectrum of HDP

HDP can be classified into several distinct but often interconnected conditions, all of which are characterized by high blood pressure during pregnancy.

• Gestational Hypertension: This condition is defined by the new onset of hypertension after 20 weeks of gestation in a woman who was previously normotensive.² The diagnosis requires two separate blood pressure (BP) readings of at least 140/90 mm Hg, taken a minimum of 4 hours apart.³ Importantly, gestational hypertension is distinguished from preeclampsia by the absence of proteinuria or other signs of maternal organ dysfunction.⁴ The blood pressure levels in women with gestational hypertension typically return to normal in the postpartum period.⁵
• Preeclampsia: Preeclampsia is a more serious, pregnancy-specific condition defined by new-onset hypertension after 20 weeks of gestation, accompanied by either proteinuria or other indicators of maternal organ dysfunction.¹ While historically the presence of proteinuria was a prerequisite for diagnosis, current guidelines from organizations such as the American College of Obstetricians and Gynecologists (ACOG) recognize that multi-systemic signs can be present in its absence.⁵ These “severe features” include a systolic BP of at least 160 mm Hg or a diastolic BP of at least 110 mm Hg, thrombocytopenia (platelet count less than
  100×109 L), renal insufficiency (serum creatinine greater than 1.1 mg/dl), impaired liver function, pulmonary edema, or new-onset neurological symptoms such as severe headache or visual disturbances.³ A woman with gestational hypertension who develops severe-range blood pressures, even without proteinuria, is now diagnosed with preeclampsia with severe features.⁵ This reclassification reflects a growing understanding that multi-systemic involvement is the primary indicator of disease severity, not just the presence of protein in the urine.
• Eclampsia: This represents the most severe manifestation of HDP. It is defined as the onset of convulsions or seizures in a woman with preeclampsia and is a life-threatening emergency.³ Eclampsia affects a small percentage of pregnancies, approximately 1 in 1,600, and typically develops near the end of the gestational period.³
• HELLP Syndrome: A rare but life-threatening complication, HELLP syndrome is considered a severe variant of preeclampsia or eclampsia.³ The acronym stands for
  Hemolysis, Elevated Liver enzymes, and Low Platelet count, reflecting the characteristic damage to blood cells and liver function.³

2.2. Epidemiology and Public Health Significance

HDP affects approximately 5% to 10% of pregnancies globally and is a leading cause of maternal and fetal morbidity and mortality worldwide.¹ Preeclampsia alone complicates 3% to 5% of all pregnancies in the U.S. and up to 8% of all pregnancies worldwide.³ The incidence of HDP, particularly its more severe forms, has been on the rise over the last two decades.¹¹ This trend underscores the increasing public health burden of these conditions and the urgent need for improved prevention, diagnosis, and management strategies. The long-term consequences of HDP extend far beyond the peripartum period, affecting the lifelong health trajectories of both the mother and her child.⁶

3. Pathophysiology and Risk Stratification: Beyond a Simple Increase in Blood Pressure

The pathogenesis of HDP, particularly preeclampsia, is a complex, multifactorial process that remains a topic of active research. While the precise etiology is often described as a “disease of theories” ¹³, a central and well-established pathophysiological cascade underpins its clinical manifestations. A thorough understanding of this cascade is essential for effective risk stratification and the development of targeted interventions.

3.1. The Placental and Endothelial Cascade

The leading theory posits that the primary insult in preeclampsia originates from the placenta, not the maternal cardiovascular system itself. In a normal early pregnancy, trophoblast cells invade the maternal decidua and remodel the spiral arteries, transforming them into wide, low-resistance, high-capacity vessels to ensure adequate blood flow to the developing fetus.¹⁴ This process is crucial for supporting fetal development.

In preeclampsia, however, this process is defective.¹⁴ The extravillous trophoblast cells fail to adequately remodel the spiral arteries, leaving them as narrow, high-resistance vessels. This leads to a state of placental ischemia—a lack of adequate blood flow—and subsequent oxidative stress.¹⁴ This physiological stress triggers the placenta to release a host of antiangiogenic and proinflammatory factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1), into the maternal circulation.⁹

The systemic release of these factors is the proximate cause of the widespread maternal endothelial dysfunction that characterizes HDP.⁹ The dysfunction of the endothelial lining of blood vessels throughout the body leads to the clinical signs of the disease: hypertension, proteinuria, and systemic organ damage to the kidneys, liver, brain, and other systems.⁶ This understanding of the disease’s origin—starting in the placenta and manifesting systemically—is a critical piece of modern clinical practice. It explains why delivery of the placenta is the only definitive resolution to the condition, as it removes the source of the damaging factors.⁹ This causal chain provides a robust rationale for a preventive approach that seeks to address the placental issues early in pregnancy.

3.2. Identified Risk Factors

A comprehensive understanding of risk factors is fundamental for identifying individuals who may benefit from preventive measures and heightened surveillance. These risk factors can be broadly categorized as high-risk and moderate-risk.

• High-Risk Factors: These are potent predictors of HDP and include a history of a hypertensive disorder in a previous pregnancy, chronic hypertension (present before 20 weeks of gestation), chronic kidney disease, type 1 or type 2 diabetes, and autoimmune disorders such as systemic lupus erythematosus or antiphospholipid syndrome.⁴ The presence of just one of these factors places a woman at significantly increased risk.
• Moderate-Risk Factors: These factors are associated with an increased likelihood of HDP, and the presence of two or more of them often warrants preventive intervention. They include nulliparity (a woman’s first pregnancy), multiple gestations (e.g., twins or triplets), obesity (high BMI), a family history of preeclampsia, and advanced maternal age (35 years or older) or age younger than 20.⁴ A prolonged interval of more than 10 years since a previous pregnancy is also a moderate risk factor.¹⁹

Socio-demographic factors also play a significant, though less understood, role. One study found that illiteracy and being a “housewife” were independently associated with a greater risk of HDP, highlighting that risk is not purely biological but can be influenced by socioeconomic conditions, health literacy, and access to care.¹⁶ This broader view of risk requires clinicians and public health practitioners to adopt a holistic, patient-centered approach that accounts for the complete lived experience of a pregnant individual.

A systematic approach to risk stratification is a cornerstone of effective HDP management. The table below consolidates the risk factors that should be considered during prenatal care.

Table 1: Risk Factors for Hypertensive Disorders of Pregnancy

Risk Level	Risk Factors
High Risk	– Previous hypertensive disorder of pregnancy, including preeclampsia 16	– Chronic hypertension 4	– Chronic kidney disease 4	– Type 1 or Type 2 diabetes 4	– Autoimmune diseases (e.g., systemic lupus erythematosus, antiphospholipid syndrome) 17	– Multiple gestations (twins, triplets) 4
Moderate Risk	– Nulliparity (first pregnancy) 4	– Family history of preeclampsia 16	– Age younger than 20 or older than 35 4	– Obesity (high body mass index) 17	– More than 10 years since previous pregnancy 19	– Use of in vitro fertilization 19
Socio-demographic	– Illiteracy 16	– Lack of occupation / “housewife” 16	– African-American race 4

4. Prevention and Early Intervention Strategies

Given the severe potential consequences of HDP, preventive and early intervention strategies are of paramount importance. The contemporary approach combines targeted pharmacological prophylaxis with evidence-based lifestyle modifications to mitigate risk in susceptible populations.

4.1. Pharmacological Prevention: Low-Dose Aspirin (LDA)

Low-dose aspirin is currently the only drug with established evidence for the prevention of preeclampsia.²⁰ Its use is recommended for women with one or more high-risk factors or multiple moderate-risk factors for the disease.¹⁷ The mechanism of action is primarily thought to involve its antiplatelet properties, which inhibit platelet aggregation and may prevent the formation of small thromboses that can cause organ damage.²⁴

The efficacy of low-dose aspirin is highly dependent on both the dosage and the timing of initiation. Professional societies, including ACOG, typically recommend a daily dose of 81 mg.¹⁸ Some studies, however, suggest that a higher dose, such as 100-150 mg, may be more effective.¹⁸ The timing of initiation is equally crucial for its effectiveness, as it must be started early in the pregnancy to influence the placental development process. The recommendation is to begin daily low-dose aspirin between weeks 12 and 16 of gestation and to continue it until delivery.¹⁸ Evidence from a review of 45 randomized trials involving over 20,000 pregnant women confirmed that starting aspirin before 16 weeks gestation significantly reduces the incidence of preeclampsia, severe preeclampsia, and fetal growth restriction.¹⁸

Aspirin is considered safe for use during pregnancy, with studies finding no increased risk of infant loss, growth problems, or harm to cognition.¹⁸ Its safety profile and proven, albeit moderate, benefits make it a foundational component of preventive care for at-risk pregnancies.¹⁷

4.2. Lifestyle and Behavioral Interventions

Beyond pharmacotherapy, lifestyle interventions offer a significant opportunity to reduce the risk of HDP, often acting as a complementary strategy to medication.

• Exercise: Regular, moderate-intensity physical activity has been shown to be a powerful preventive measure. Studies indicate that exercise may reduce the risk of gestational hypertension and preeclampsia by 30% to 40%.²⁰ The Community Preventive Services Task Force recommends exercise programs that begin before the 16th week of pregnancy and continue through birth.²⁵ These programs can include supervised exercise classes or regular walking sessions of 90 to 150 minutes per week.²⁵ The protective effect of exercise is believed to stem from its ability to improve cardiovascular conditioning, lower blood pressure, reduce oxidative stress, and stimulate vascular and placental growth.²⁶
• Diet: Dietary interventions, such as adherence to the Dietary Approaches to Stop Hypertension (DASH) diet, have shown promising results. This diet, characterized by a high intake of fruits, vegetables, whole grains, and low-fat dairy, while limiting saturated fats and refined sugars, has been associated with a 35% to 45% reduced risk of preeclampsia in observational studies.²⁷ The benefits of the DASH diet are attributed to mechanisms that improve blood pressure regulation, reduce inflammation, and enhance endothelial function, which directly addresses the core pathophysiology of HDP.²⁷
• Other Interventions: Calcium supplementation is another a recommendation for prevention in specific populations. The World Health Organization (WHO) recommends a daily supplement of 2 grams of calcium for pregnant women with a low dietary intake of calcium (less than 600 mg/day) as it has been linked to a reduction in preeclampsia risk.²²

A comprehensive approach to prevention involves the synergistic application of these strategies. For a woman with multiple risk factors, the most effective management plan would not be to choose between aspirin or a healthy diet, but to combine a daily low-dose aspirin regimen with a consistent program of moderate exercise and a DASH-style diet. This integrated approach, which fuses targeted pharmacological intervention with general health promotion, exemplifies a modern, holistic view of prenatal care.

5. Acute Management and Treatment During Pregnancy

Once a hypertensive disorder is diagnosed, the focus of management shifts to acute care, with the primary goals of controlling maternal blood pressure, preventing severe complications, and ensuring fetal well-being. This phase of care requires meticulous monitoring, judicious use of pharmacotherapy, and timely decision-making regarding delivery.

5.1. Diagnosis and Monitoring

Effective management hinges on accurate and continuous monitoring. Routine prenatal care involves regular blood pressure measurements, urine protein checks, and blood tests to assess liver and kidney function and platelet count.⁴ These measures are essential for differentiating between gestational hypertension and preeclampsia and for monitoring disease progression.⁴

• Home Monitoring: Self-measured blood pressure (SMBP) is an important self-care option that is increasingly being integrated into clinical practice. ACOG and other professional bodies acknowledge the accuracy of several self-measured BP devices for pregnant women with HDP.²⁰ The WHO has also released a digital adaptation kit to help pregnant women manage hypertensive disorders at home.²⁹ Patients should be educated on the proper technique for taking their blood pressure and, crucially, what readings should prompt immediate medical attention. A reading of 160/110 mm Hg or higher requires seeking urgent medical care and should not be deferred to a scheduled appointment.²⁸ This shift towards patient-empowered monitoring is critical, as HDP can progress rapidly between clinical visits, and timely intervention can prevent catastrophic events like stroke.³⁰
• Advanced Diagnostics: While traditional tests remain the standard, the development of new biomarkers offers a glimpse into the future of HDP diagnostics. Novel biomarkers, such as the soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) ratio, are now being used in some settings. These biomarkers can help clinicians better stratify patient risk and, with their high negative predictive value, can confidently “rule out” preeclampsia within a week, potentially reducing unnecessary hospital admissions for suspected cases.¹⁰ The first-ever FDA-approved test for preeclampsia was approved in 2023, which measures the sFlt-1/PlGF ratio to aid in clinical management.¹¹

5.2. Pharmacological Management

The goal of pharmacological management is to lower maternal blood pressure to prevent complications like stroke without compromising placental blood flow and fetal well-being. This requires a careful balancing act and the use of medications proven to be safe and effective in pregnancy.

• First-Line Agents for Non-Severe Hypertension: For non-severe hypertension (BP between 140/90 and 159/109 mm Hg), oral medications are used. First-line agents include Labetalol (a beta-blocker), Nifedipine XL (a calcium channel blocker), and Methyldopa (an alpha agonist).² Methyldopa, in particular, has been extensively studied and is often recommended as a first-line oral agent in pregnancy.³⁴ The target blood pressure for treatment in pregnancy is now often lower than in the past, with guidelines from NICE recommending a target of 135/85 mm Hg.³³
• Management of Severe Hypertension: For acute, severe hypertension (BP ≥ 160/110 mm Hg), rapid-acting intravenous (IV) or oral medications are necessary to prevent maternal complications. The recommended agents for this purpose are IV Labetalol, IV Hydralazine, or oral immediate-release Nifedipine.²
• Contraindicated Medications: A critical component of pharmacological management is the strict avoidance of certain drug classes that are harmful to the fetus. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are contraindicated throughout pregnancy due to their teratogenic and fetotoxic effects, which can cause severe birth defects, including renal and skull defects.¹⁷ Diuretics, such as furosemide and hydrochlorothiazide, are also generally avoided due to concerns about reduced maternal blood volume and placental hypoperfusion.³⁴ Women with chronic hypertension who are on these medications should be reviewed before pregnancy and transitioned to safer alternatives.¹⁷
• Seizure Prevention: In cases of severe preeclampsia, the anticonvulsant medication of choice is magnesium sulfate, administered to prevent and treat eclamptic seizures.⁷

Table 2: Pharmacological Management of HDP

Condition	Recommended Medications	Contraindicated Medications	Special Considerations
Non-Severe Antepartum Hypertension	– Labetalol (β-blocker) 2	– Nifedipine XL (calcium channel blocker) 2	– Methyldopa (α agonist) 2	– ACE inhibitors 17	– ARBs 17	– Diuretics 34	– Propranolol 34	– Goal BP often set at 135/85 mm Hg 33	– Methyldopa can cause dry mouth, drowsiness, and is poorly tolerated 2	– Nifedipine XL is preferred over short-acting formulations due to risk of sudden BP drops 34
Acute Severe Antepartum Hypertension	– Labetalol (IV) 2	– Hydralazine (IV) 2	– Immediate-release Nifedipine (PO) 2	– ACE inhibitors 17	– ARBs 17	– Rapid BP lowering is crucial to prevent stroke 17	– Sublingual administration should be avoided due to risk of hypoperfusion 22	– Avoid Nifedipine with Magnesium Sulfate due to risk of excessively low BP 34
Postpartum Hypertension	– Labetalol 2	– Nifedipine XL 2	– Enalapril (ACE inhibitor) 2	– Methyldopa (avoid if postnatal depression a concern) 37	– Methyldopa (association with postnatal depression) 17	– ACE inhibitors (e.g., Enalapril, Lisinopril) and ARBs (e.g., Losartan) can be used postpartum and are considered safe during lactation 2	– Monitor for potential decrease in breast milk production with diuretics 2

5.3. Managing Complications and Delivery

The primary management strategy for preeclampsia is to stabilize the mother and the fetus until the optimal time for delivery. Delivery of the placenta is the only definitive treatment, as it removes the source of the pathophysiology.⁹ The decision to deliver is a clinical one, dependent on the severity of the disease, gestational age, and the overall health of the mother and baby.⁷ In cases of non-severe preeclampsia, delivery may be recommended after 37 weeks, while severe cases often necessitate delivery before 37 weeks to prevent life-threatening complications for both mother and child.⁷ Corticosteroids may also be administered to promote fetal lung maturation if an early delivery is anticipated.⁷

6. Postpartum and Long-Term Health Implications

A critical and often overlooked component of HDP management is the care that extends beyond delivery. The conventional wisdom that delivery is a “cure” for HDP is a dangerously outdated concept, as current research reveals that the condition leaves a lasting physiological imprint with profound lifelong consequences for both mother and child.

6.1. The Critical Postpartum Period

The postpartum period is a time of heightened risk for women with a history of HDP. Following delivery, the withdrawal of placental hormones and rapid fluid shifts lead to a physiological increase in blood pressure, which typically peaks between days 3 and 7 postpartum.² A majority of hypertension-related maternal deaths occur during this window, underscoring the necessity of continued vigilance.² Preeclampsia can also manifest for the first time after delivery, a condition known as postpartum preeclampsia, which can occur up to six weeks postpartum.³

The patient’s stories collected in this report highlight the need for continued monitoring and patient education during this critical phase.³⁰ Women must be aware of the warning signs of postpartum preeclampsia, such as severe headaches, vision changes, and abdominal pain, and be instructed to seek immediate medical care if symptoms arise.³ The use of magnesium sulfate may be continued for up to 24 hours postpartum to prevent seizures, and antihypertensive medications may be required for several weeks.³² A smooth transition of care from the obstetrician to a primary care physician or cardiologist is vital to ensure ongoing management of cardiovascular risk factors.²

6.2. Long-Term Maternal Health Risks

A history of HDP, particularly preeclampsia, serves as a powerful predictor of future health complications. It is now formally recognized by organizations like the American Heart Association as an independent risk factor for cardiovascular disease (CVD) and stroke.⁹

• Cardiovascular and Cerebrovascular Risks: Research shows that women with a history of preeclampsia are at a three- to fourfold increased risk of developing high blood pressure later in life, a twofold increased risk for heart disease and stroke, and a fourfold increased risk of heart failure.¹² These risks are particularly pronounced within the first 10 years following the affected pregnancy.⁴¹ HDP also lowers the age at which chronic hypertension onset occurs, exposing women to longer periods of organ damage.⁴¹
• Renal Risks: The lasting impact of HDP extends to other organ systems. The risk of end-stage renal disease is 5 to 12 times higher in women with a history of preeclampsia.⁴¹
• Mental Health Risks: A preeclamptic pregnancy is often a traumatic event, and this can have significant psychological consequences. Women who have experienced severe HDP, eclampsia, or HELLP syndrome have a higher incidence of psychiatric complications, including post-traumatic stress disorder (PTSD), postpartum depression (PPD), and anxiety.⁴² The biological mechanisms behind this may involve damage to the blood-brain barrier from antiangiogenic and pro-inflammatory factors, which can lead to long-term structural and functional cerebral changes.⁴²

6.3. Long-Term Offspring Health Risks

The effects of HDP are not limited to the mother; the intrauterine environment of a preeclamptic pregnancy can permanently alter fetal development, a concept known as the “developmental origins of health and disease”.⁶ This makes HDP an intergenerational health concern.

• Cardiovascular and Metabolic Risks: Children born to mothers with HDP face an increased risk of developing high blood pressure in childhood and adulthood.⁶ Even infants born from preeclamptic pregnancies with a healthy birth weight exhibit higher systolic blood pressure as they grow.⁴¹ The high placental resistance that can occur in HDP can alter the anatomy of the developing fetal heart, leading to changes such as a smaller right ventricle at birth and thicker ventricle walls at three months of age.¹² This suggests a predisposition to coronary heart disease and/or heart failure later in life.¹² The risk of stroke in offspring is also doubled in later life.⁴⁵
• Other Risks: HDP can lead to preterm birth and intrauterine growth restriction (IUGR), both of which are independent risk factors for developmental delays, cerebral palsy, and chronic conditions like hypertension and diabetes in adulthood.⁶

The table below summarizes the lasting health consequences for both mothers and their children.

Table 3: Long-Term Health Risks and Follow-Up for Mothers and Offspring

Individual	Identified Health Risks	Recommended Follow-up Care
Mother	– Increased risk for chronic hypertension (3-4x) 12	– Increased risk for coronary heart disease (2x) 40	– Increased risk for heart failure (4x) 41	– Increased risk for stroke (2x) 40	– Increased risk for end-stage renal disease (5-12x) 41	– Higher incidence of PTSD, PPD, and anxiety 42	– Lifelong cardiovascular risk factor management 2	– Regular BP monitoring (aim for BP <130/80 mm Hg) 40	– Healthy lifestyle changes (e.g., diet, exercise, smoking cessation) 40	– Seamless transition of care from obstetrician to primary care or cardiologist 2	– Psychological support and mental health screening 41
Offspring	– Elevated blood pressure in childhood and adulthood 6	– Altered cardiac structure (e.g., thicker ventricle walls) 12	– Increased risk for coronary heart disease and heart failure 12	– Increased risk for stroke 45	– Increased risk for developmental delays and chronic conditions (due to prematurity/IUGR) 26	– Dedicated pediatric cardiovascular surveillance 44	– Monitoring of blood pressure starting in childhood 44	– Early screening for developmental delays 41

7. The Patient Experience and Psychological Impact

While clinical and scientific data provide a foundation for HDP management, understanding the patient experience adds a crucial dimension. Patient narratives and research on mental health outcomes reveal a significant emotional and psychological burden that can profoundly affect survivors and their families.

7.1. The Psychological Burden

Patient stories illustrate the immense trauma of an HDP diagnosis and its management. Many women describe feeling a sense of dread and helplessness, often exacerbated by the rapid onset of severe symptoms like skyrocketing blood pressure, headaches, and abdominal pain.³⁰ The experience of emergency delivery, often via C-section, and a subsequent neonatal intensive care unit (NICU) stay for the premature infant, can be deeply distressing.³⁰ This stress, combined with the unexpected nature of the medical emergency, can lead to serious psychiatric complications.

Multiple studies suggest that women who have endured severe HDP have a higher incidence of post-traumatic stress disorder (PTSD) and postpartum mood disorders (PPMD), including depression and anxiety, than women without these complications.⁴² The psychological burden can be long-lasting, with one survivor expressing that she was “grieving for the loss of my pregnancy” and the fact that her child was not “100% healthy”.³¹ The trauma can also strain relationships, with experts acknowledging that the experience is challenging for both partners and requires proactive steps to strengthen the relationship.⁴³

7.2. The Role of Patient Advocacy and Education

Patient narratives underscore the critical need for women to feel empowered and to trust their instincts. One survivor recounts how she felt symptoms but dismissed them as normal pregnancy discomfort, later regretting that she was “embarrassed to ask too many questions”.³¹ Another patient’s persistence in daily home blood pressure monitoring and presenting her logs to her doctor was ultimately what led to a life-saving intervention.³⁰ These stories demonstrate that the patient is often the first to notice symptoms that signal a rapid progression of the disease.

Effective patient education is therefore the “first line of defense”.⁴⁷ Educating patients in clear, non-technical language about the warning signs and what to do if they appear (e.g., call the provider immediately for a BP of 140/90 mm Hg and seek immediate medical care for a BP of 160/110 mm Hg) is a crucial preventive measure.²⁸ The Preeclampsia Foundation and Postpartum Support International (PSI) provide vital resources, including hotlines, support groups for birth trauma and NICU parents, and expert directories to help survivors understand their experience and find coping mechanisms.⁴³

A comprehensive management plan for HDP must recognize the psychological burden as a central component of care. It requires moving beyond the purely clinical to a model that integrates robust patient education, empathetic communication, and readily available psychological support to address the full spectrum of HDP’s impact.

8. Future Directions and Unmet Needs in HDP Research

The field of HDP management is in a state of rapid evolution, but significant gaps remain between scientific understanding, diagnostic capability, and clinical practice. Addressing these unmet needs is essential for improving maternal and child health outcomes.

8.1. Advancing Diagnostic and Predictive Tools

Despite more than a century of research, clinicians still rely on “antiquated tools and schemes of the 19th Century” ¹¹ for diagnosis, primarily blood pressure and urine protein measurements. The clinical presentation of HDP can be highly variable, making a timely and accurate diagnosis challenging.¹¹ While new biomarkers like the sFlt-1/PlGF ratio have shown great promise in risk stratification and “ruling out” preeclampsia with high accuracy, they have yet to achieve widespread clinical use.⁹ The urgent need is for the development and implementation of simple, rapid, and accurate predictive tests that can identify high-risk women early in pregnancy, enabling clinicians to initiate preventive measures more effectively and reducing wasteful, repetitive surveillance for low-risk patients.¹¹

8.2. Novel Therapeutic and Preventive Strategies

Low-dose aspirin remains the only pharmacological intervention with strong evidence for prevention.²² There is a critical need for new, effective therapies that can address the underlying placental and endothelial dysfunction. Promising areas of research, such as the use of statins for prevention, have shown some promise in animal models and pilot studies without apparent safety concerns.²³ However, these require larger, rigorous randomized controlled trials to validate their efficacy and safety in human pregnancies.

8.3. Optimizing Long-Term Care

Perhaps the most significant challenge lies in optimizing long-term care. While the lifelong health risks for both mothers and children are well-documented, the mechanisms driving these long-term consequences are still not fully understood and require further exploration.⁹ The fragmentation of care that often follows an HDP diagnosis—with a patient being discharged from obstetric care without a formalized follow-up plan—is a major contributor to poor long-term outcomes.² There is an urgent need to establish standardized, long-term follow-up guidelines for HDP survivors and their children. The development of innovative care models, such as multidisciplinary postpartum clinics that facilitate a smooth transition of care to primary care or cardiology, is a promising step towards ensuring that the life-long health risks of HDP are recognized and managed effectively.²

The ongoing challenge for the medical community is not just to discover new interventions, but to actively advocate for and facilitate the translation of new knowledge into routine, evidence-based clinical practice. This will require collaboration between researchers, clinicians, public health bodies, and patient advocacy groups to ensure that the transformative insights from recent years lead to concrete improvements in care for all individuals affected by HDP.

Works cited

1. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance | The BMJ, accessed August 13, 2025, https://www.bmj.com/content/366/bmj.l5119.abstract
2. Hypertension in Pregnancy and Postpartum: Current Standards and Opportunities to Improve Care | Circulation, accessed August 13, 2025, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.073302
3. Gestational hypertension vs. preeclampsia: A comparison – Medical News Today, accessed August 13, 2025, https://www.medicalnewstoday.com/articles/gestational-hypertension-vs-preeclampsia
4. Gestational Hypertension | Children’s Hospital of Philadelphia, accessed August 13, 2025, https://www.chop.edu/conditions-diseases/gestational-hypertension
5. Diagnosing Preeclampsia – Key Definitions and ACOG Guidelines – The ObG Project, accessed August 13, 2025, https://www.obgproject.com/2017/01/08/diagnosing-preeclampsia-key-definitions/
6. Lasting Effects of Intrauterine Exposure to Preeclampsia on Offspring and the Underlying Mechanism – PMC, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6736667/
7. Preeclampsia – Diagnosis & treatment – Mayo Clinic, accessed August 13, 2025, https://www.mayoclinic.org/diseases-conditions/preeclampsia/diagnosis-treatment/drc-20355751
8. www.chop.edu, accessed August 13, 2025, https://www.chop.edu/conditions-diseases/gestational-hypertension#:~:text=Preeclampsia%20is%20diagnosed%20when%20a,seizures%20resulting%20from%20the%20condition.
9. Preeclampsia beyond pregnancy: long-term consequences for mother and child – PMC, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7311709/
10. Clinical tools and biomarkers to predict preeclampsia – PMC, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8718967/
11. Developing Accurate Preeclampsia Tests, accessed August 13, 2025, https://www.preeclampsia.org/biomarkers
12. Pregnancy-Induced Hypertension has Long-Term Health … – OHSU, accessed August 13, 2025, https://www.ohsu.edu/school-of-medicine/moore-institute/pregnancy-induced-hypertension-has-long-term-health-implications
13. Research – Preeclampsia Foundation, accessed August 13, 2025, https://www.preeclampsia.org/research
14. Epidemiology and Pathophysiology of Preeclampsia: New Mechanistic Insights | Hypertension – American Heart Association Journals, accessed August 13, 2025, https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.124.24117?doi=10.1161/HYPERTENSIONAHA.124.24117
15. Preeclampsia pathophysiology and adverse outcomes during, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10060641/
16. Risk Factors for Hypertensive Disorders in Pregnancy: A Report from the Maroua Regional Hospital, Cameroon, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3719289/
17. Hypertension in pregnancy: the NICE guidelines | Heart, accessed August 13, 2025, https://heart.bmj.com/content/97/23/1967
18. Ask About Aspirin – Preeclampsia Foundation, accessed August 13, 2025, https://www.preeclampsia.org/aspirin
19. Preeclampsia – Symptoms & causes – Mayo Clinic, accessed August 13, 2025, https://www.mayoclinic.org/diseases-conditions/preeclampsia/symptoms-causes/syc-20355745
20. Hypertensive Disorders of Pregnancy | Million Hearts®, accessed August 13, 2025, https://millionhearts.hhs.gov/tools-protocols/tools/hypertension-disorders-pregnancy.html
21. High blood pressure and pregnancy: Know the facts – Mayo Clinic, accessed August 13, 2025, https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/pregnancy/art-20046098
22. Pre-Eclampsia and Eclampsia: An Update on the Pharmacological Treatment Applied in Portugal – PMC – PubMed Central, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5872351/
23. NOVEL INTERVENTIONS FOR THE PREVENTION OF PREECLAMPSIA – PMC, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8237364/
24. Application of low dose aspirin in pre-eclampsia – Frontiers, accessed August 13, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1111371/full
25. Pregnancy Health: Exercise Programs to Prevent Gestational Hypertension – Healthy People 2030 | odphp.health.gov, accessed August 13, 2025, https://odphp.health.gov/healthypeople/tools-action/browse-evidence-based-resources/pregnancy-health-exercise-programs-prevent-gestational-hypertension
26. Exercising to Reduce the Effects of Preeclampsia, accessed August 13, 2025, https://www.abclawcenters.com/blog/exercising-to-reduce-the-effects-of-preeclampsia/
27. DASH Diet and Preeclampsia Prevention: A Literature Review – MDPI, accessed August 13, 2025, https://www.mdpi.com/2072-6643/17/12/2025
28. Blood Pressure – Preeclampsia Foundation, accessed August 13, 2025, https://www.preeclampsia.org/blood-pressure
29. New digital tool to support self-monitoring of blood pressure in …, accessed August 13, 2025, https://www.who.int/news/item/15-07-2025-new-digital-tool-to-support-self-monitoring-of-blood-pressure-in-pregnancy
30. My Preeclampsia Experience: Could It Have Been Avoided?, accessed August 13, 2025, https://www.preeclampsia.org/our-stories/my-preeclampsia-experience-could-it-have-been-avoided
31. Surviving Preeclampsia—What We Need for More Success Stories – Roche Diagram, accessed August 13, 2025, https://rochediagram.com/surviving-preeclampsia/
32. Pre-eclampsia – Treatment – NHS, accessed August 13, 2025, https://www.nhs.uk/conditions/pre-eclampsia/treatment/
33. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance – DickyRicky, accessed August 13, 2025, http://dickyricky.com/Medicine/Papers/2019_09_21%20BMJ%20Diagnosis%20and%20management%20of%20hypertension%20in%20pregnancy%20summary%20of%20updated%20NICE%20guidance%20NG133.pdf
34. Antihypertensive Medications for Pregnant Women – Healthline, accessed August 13, 2025, https://www.healthline.com/health/pregnancy/chronic-hypertension-medicine
35. pmc.ncbi.nlm.nih.gov, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8542489/
36. Postpartum preeclampsia – Diagnosis & treatment – Mayo Clinic, accessed August 13, 2025, https://www.mayoclinic.org/diseases-conditions/postpartum-preeclampsia/diagnosis-treatment/drc-20376652
37. Postpartum Hypertension, Guideline for Management (322) – Right Decision Service, accessed August 13, 2025, https://rightdecisions.scot.nhs.uk/maternity-gynaecology-guidelines/maternity/common-obstetric-problems-intrapartum-labour-ward/postpartum-hypertension-guideline-for-management-322/
38. Postpartum Preeclampsia, accessed August 13, 2025, https://www.preeclampsia.org/postpartum-preeclampsia
39. Adriana’s story – Action on Pre-eclampsia, accessed August 13, 2025, https://action-on-pre-eclampsia.org.uk/adrianas-story/
40. Understanding Long-term Effects Of Preeclampsia And Taking Charge, accessed August 13, 2025, https://www.preeclampsia.org/the-news/Healthcare-practices/understanding-long-term-effects-of-preeclampsia-and-taking-charge
41. Long term impact of PE – Intignus Biotech, accessed August 13, 2025, https://intignusbiotech.com/2024/10/24/long-term-impact-of-pe/
42. Preeclampsia and postpartum mental health: mechanisms and clinical implications, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/34538205/
43. Not Just Physical: The Psychological Burden Of Preeclampsia And …, accessed August 13, 2025, https://www.preeclampsia.org/the-news/community-support/not-just-physical-the-psychological-burden-of-preeclampsia
44. Preeclampsia and cardiovascular risk in offspring : Journal of Pediatrics – Ovid, accessed August 13, 2025, https://www.ovid.com/journals/jped/fulltext/10.1016/j.jpeds.2019.03.012~preeclampsia-and-cardiovascular-risk-in-offspring
45. Preeclampsia and Preterm Offspring Cardiovascular Health – Frontiers, accessed August 13, 2025, https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2021.625726/epub
46. Postpartum Support International – PSI, accessed August 13, 2025, https://postpartum.net/
47. Get Support – Preeclampsia Foundation, accessed August 13, 2025, https://www.preeclampsia.org/get-support
48. Weekly Online Support Group | Join a Free Group Today – Postpartum Support International, accessed August 13, 2025, https://postpartum.net/get-help/psi-online-support-meetings/